Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma

Journal of Hepatology, Supplement

Volumn 24, Issue 2, 1996, Pages 61-66

  Caselmann, Wolfgang H ^a   Alt, Michael ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

Alcohol; Blood transfusion; Case control studies; Cirrhosis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS DNA; VIRUS RNA;

ANTIBODY DETECTION; BLOOD TRANSFUSION; CANCER MORTALITY; CLINICAL FEATURE; CONFERENCE PAPER; CONTROLLED STUDY; GENE MUTATION; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; VIRUS REPLICATION;

CARCINOMA, HEPATOCELLULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 0029791851     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Caselmann WH. Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol 1995; 22 (Suppl. 1): 347.
2. Choo QL, Weiner AJ, Kuo G, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Graf, E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994; 9: 81-7.
4. Meyer M, Wiedorn KH, Hofschneider PH, Koshy R, Caselmann WH. A chromosome 17:7 translocation is associated with a hepatitis B virus DNA integration in human hepatocellular carcinoma DNA. Hepatology 1992; 15: 66571.
5. Caselmann WH, Meyer M, Kekulé AS, Lauer U, Hofschneider PH, Koshy R. A novel trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1990; 87: 2970-4.
6. Kekulé AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional /raw-activator. Nature 1990; 343: 457-61.
7. Wei Y, Fourel G, Ponzetto A, Silvestro M, Tiollais P, Buendia MA. Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors. J Virol 1992; 66: 5265-76.
8. Shibuya H, Irie K, Ninomiya-Tsuji J, Goebl M, Taniguchi T, Matsumoto K. New human gene encoding a positive modulator of HIV Tat-mediated transactivation. Nature 1992; 357: 700-2.
9. Resnick RH, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A, non-B posttransfusion hepatitis. Dig Dis Sci 1983; 28: 908-11.
10. Gilliam JH, Geisinger KR, Richter JE. Primary hepatocellular carcinoma following chronic non-A, non-B post-transfusion hepatitis. Ann Int Med 1984; 101: 794-5.
11. Kiyosawa K, Akahane Y, Nagata A, Furuta S. Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis. Am J Gastroenterol 1984; 79: 777-81.
12. Cohen EB, Gang DL, Zeldis JB. Primary hepatocellular carcinoma following non-specific non-B hepatitis with tumor negative for HBV DNa. Dig Dis Sci 1987; 32: 1428-30.
13. Muchmore E, Popper H, Peterson DA, Miller MF, Lieberman HM. Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee. J Med Primatol 1988; 17: 23546.
14. Yousof M, Kakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992; 27: 812-6.
15. Verbaan H, Wisell A, Lindgren S, Lindmark B, Nordenfeldt E, Eriksson S. Hepatitis C in chronic liver disease: an epidemiological study based on 565 consecutive patients undergoing liver biopsy during a 10 year period. J Intern Med 1992; 232: 33-t2.
16. Van der Poel CL. Hepatitis C virus. Epidemiology, transmission and prevention. In: Reesink HW, ed. Current Studies in Hematology and Blood Transfusion, Vol. 61. Hepatitis C Virus. Basel: S. Karger, 137-63.
17. Kew MC. Hepatitis C virus and hepatocellular carcinoma. FEMS Microbiol Rev 1994; 14: 211-20.
18. Yu MW, Chen CJ. Hepatitis B and C viruses in the development of hepatocellular carcinoma. Crit Rev Oncol Hematol 1994; 17:71-91.
19. Kaklamani E, Trichopoulos D, Tzonou A, Zavitsanos X, Koumantaki Y, Hatzakis A, Hsieh CC, Hatziyannis S. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. JAMA 1991; 265: 1974-6.
20. Chuang WL, Chang WY, Lu SN, Su WP, Lin ZY, Chen SC, Hsieh MY, Wang LY, You SL, Chen CJ. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. Cancer 1992; 69: 2052-4.
21. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Florentine G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992; 116: 97-102.
22. Nalpas B, Driss F, Pol S, Hamelin B, Housset C, Bréchot C, Berthelot P. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991; 12: 70-4.
23. Caporaso N, Romano M, Marmo R, de Sio I, Morisco F, Minerva A, Coltorti M. Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1991; 12: 367-71.
24. Vargas V, Castells L, Esteban JI. High frequency of antibodies to the hepatitis C virus among patients with hepatocellular carcinoma. Ann Intern Med 1990; 112: 232-3.
25. Bruix J, Calvet X, Costa J, Ventura M, Bruguera M, Castillo R, Barrera JM, Ercilla G, Sanchez-Taplas JM, Vail M, Bru C, Rodes J. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-5.
26. Tanaka H, Hiyama T, Okubo Y, Kitada A, Fujimoto I. Primary liver cancer incidence-rates related to hepatitis-C virus infection: a correlational study in Osaka, Japan. Cancer Cause Control 1994; 5: 61-5.
27. Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, Dioguardi N, Houghton M. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
28. Nishioka K, Watanabe J, Furuta S, Tanaka E, lino S, Suzuki H, Tsuji T, Yano M, Kuo G, Choo Q-L, Houghton M, Oda T. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67: 429-33.
29. Hasan F, Jeffers LJ, De Medina M, Reddy KR, Parker T, Schiff ER, Houghton M, Choo Q, Kuo G. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990; 12: 589-91.
30. Kiyosawa K, Sodeyama T, Tanaka E. Hepatitis C virus and hepatocellular carcinoma: Additional evidence of a causal link. Gastroenterology 1991; 100: 1145-6.
31. Ohkoshi S, Kojima H, Tawaraya H, Miyajima T, Kamimura T, Asakura H, Satoh A, Hirose S, Hijikata M, Kalo N. Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma. Jap J Cancer Res 1990; 81: 550-3.
32. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo Q-L, Houghton M, Kuo G. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6547-9.
33. Goeser T, Müller HM, Solbach C, Toex U, Kommerell B, Theilmann L. Hepatitis C virus, alcoholic cirrhosis, and hepatocellular carcinoma. Cancer Epidemiol Biomar Prev 1994; 3: 311-5.
34. Farinati F, Fagiuoli S, De Maria N, Chiaramonte M, Aneloni V, Ongaro S, Salvagnini M, Naccarato R. Anti-HCV positive hepatocellular carcinoma in cirrhosis. Prevalence, risk factors and clinical features. J Hepatol 1992; 14: 183-7.
35. Poynard T, Aubert A, Lazizi Y, Bedossa P, Hamelin B, Terris B, Naveau S, Dubreuil P, Pillot J, Chaput J-C. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991; 13: 896-901.
36. Reid AE, Jeffers LJ, Reddy KR, Aiza I, Schiff ER, Dienstag JL, Liang TJ. Hepatitis C virus genotypes and hepatocellular carcinoma. Hepatology 1994; 20: 250A.
37. Naumov NV, Chokshi S, Metivier E, Maertens G, Johnson PJ, Williams R. Hepatitis C virus genotypes and hepatocellular carcinoma. Hepatology 1994; 20. 250A.
38. Jeng JE, Tsai JF. Hepatitis C virus antibody in hepatocellular carcinoma in Taiwan. J Med Virol 1991; 34: 74-7.
39. Dazza MC, Meneses LV, Girard PM, Villaroel C, Delaporte E, Larouze B. Absence of relationship between antibodies to hepatitis C virus and hepatocellular carcinoma in Mozambique. Am J Trop Med Hyg 1993; 48: 237t2.
40. Di Bisceglie AM, Order SE, Klein JL, Waggoner JG, Sjogren MH, Kuo G, Houghton M, Choo QL, Hoofnagle JH. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86: 335-8.
41. Sbolli G, Zanetti AR, Tanzi E, Cavanna L, Civardi G, Fornari F, Di Stasi M, Buscarini L. Serum antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. J Med Virol 1990; 30: 230-2.
42. Bukh J, Miller RH, Kew MC, Purcell RH. Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma. Proc Natl Acad Sci USA 1993; 90: 1848-51.
43. Lee SD, Lee FY, Wu JC, Hwang SJ, Wang SS, Lo KJ. The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992; 69: 342-5.
44. Lee HS, Han CJ, Kim CY. Predominant etiologic association of hepatitis C virus with hepatocellular carcinoma compared with hepatitis B virus in elderly patients in a hepatitis Bendemic area. Cancer 1993; 72: 2564-7.
45. Leung NWY, Tam JS, Lai JY, Leung TWT, Lau WY, Shiu W, Li AKC. Does hepatitis C virus infection contribute to hepatocellular carcinoma in Hong Kong? Cancer 1992; 70: 40-4.
46. Schlüter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene 1994; 9: 3335-44.
47. Gerber MA, Shieh CYS, Shim KS, Swan NT, Demetris AJ, Schwartz M, Akyol G, Dash S. Detection of replicative C virus sequences in hepatocellular carcinoma. Am J Pathol 1992; 141: 1271-7.
48. Horiike N, Nonaka T, Kumamoto I, Kajino K, Onji M, Ohta Y. Hepatitis C virus plus- and minus-strand RNA i hepatocellular carcinoma and adjoining nontumorous liver. J Med Virol 1993; 41: 312-5.
49. Haruna Y, Hayashi N, Kamada T, Hytiroglou P, Thung SN, Gerber MA. Expression of hepatitis C virus in hepatocellular carcinoma. Cancer 1994; 73: 2253-8.
50. Takamisawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Andoh T, Yoshida I, Okayama H. Structure and organisation of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 1105-13.
51. Hino O, Kajino K. Hepatitis virus-related hepatocarcinogenesis. Intervirology 1994; 37: 133-5.
52. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda S. p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res. 1994; 54. 231-5.
53. Levrero M, Tagger A, Balsano C, De Marzio E, Avataggiati ML, Natoli G, Diop D, Villa E, Diodati G, Albert! A. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma 1991; 12: 60-3.
54. Zavitsanos X, Hatzakis A, Kaklamani E, Tzonou A, Toupadaki N, Broeksma C, Chrispeels J, Troonen H, Hadziyannis S, Hsieh C-C, Alter H, Trichopoulos D. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitis C virus peptides. Cancer Res 1992; 52: 5364-7.
55. Zala G, Havelka J, Altorfer J, Joller-Jemelka HJ, Risti B, Meier B, Schmid M, Bühler H. Hepatitis-C-Virus und Hepatom. Schweiz Med Wbchenschr 1992; 122: 194-7.
56. Yu MC, Tong MJ, Coursaget P, Ross RK, Govindarajan S, Henderson BE. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Nat! Cancer Inst 1990; 82: 10381.
57. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Kuo GC, Chen CJ. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990; 162: 817-22.
58. Boonmar S, Pojanagaroon B, Watanabe Y, Tanaka Y, Saito I, Miyamura T. Prevalence of hepatitis C virus antibody among healthy blood donors and non-A, non-B hepatitis patients in Thailand. Jap J Med Sci Biol 1990; 43: 29-36.
59. Tomimatsu M, Ishiguro N, Taniai M, Okuda H, Saito A, Obata H, Yamamoto M, Takasaki K, Nakano M. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 1993; 72: 683-8.
60. Tanaka K, Hirohata, Koga S, Sugimachi K, Kanematsu T, Ohryohji F, Nawata H, Ishibashi H, Maeda Y, Kiyokawa H, Tokunaga K, Irita Y, Takeshita S, Arase Y, Nishino N. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res. 1991; 51: 2842-7.
61. Ramesh R, Munshi A, Panda SK. Prevalence of hepatitis C virus antibodies in chronic liver disease and hepatocellular carcinoma patients in India. J Gastroenterol Hepatol 1992; 7: 393-5.
62. Peters M, Wellek S, Dienes HP, Junginger T, Meyer J, Meyer zum Büschenfelde KH, Gerken G. Epidemiology of hepatocellular carcinoma. Evaluation of viral and other risk factors in a low-endemic area for hepatitis B and C. Z. Gastroenterology 1994; 32: 146-51.
63. Yu MW, You SL, Chang AS, Lu SN, Liaw YF, Chen CJ. Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 1991; 51: 5621-5.
64. Srivatanakul P, Parkin DM, Khlat M, Chenvidhya D, Chotivan P, Insiripong S, L'Abbe KA, Wild CP. Liver cell cancer in Thailand. II. A case/control study of hepatocellular carcinoma. Int J Cancer 1991; 48: 329-32.
65. Coursaget P, Leboulleux D, Le Cann P, Bao O, Coil-Seek AM. Hepatitis C virus infection in cirrhosis and primary hepatocellular carcinoma in Senegal. Trans R Soc Trop Med Hyg 1992; 86: 552-3.